Estrella Immunopharma, Inc. (ESLA) vs Karyopharm Therapeutics Inc. (KPTI)
A side-by-side comparison of Estrella Immunopharma, Inc. and Karyopharm Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ESLA
Estrella Immunopharma, Inc.
$0.42HealthcareDelayed quote: Oct 6, 2026, 1:53 PM EDT
KPTI
Karyopharm Therapeutics Inc.
$0.67HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — ESLA vs KPTI
growth of $100 · dividends reinvested · last 5yESLA -95.5% (-46.2%/yr)KPTI -99.2% (-61.9%/yr)ESLA compounded faster over this window
Log scale — wide-divergence pair
ESLA KPTI
ESLA vs KPTI: by the numbers
- •ESLA is the larger company ($18M vs $15M market cap).
- •Both run net losses; ESLA's is the smaller (0.00% vs -153.28% net margin).
Metrics side by side
Valuation
| Metric | ESLA | KPTI |
|---|---|---|
| P/S ratio | N/A | 0.10 |
Profitability
| Metric | ESLA | KPTI |
|---|---|---|
| Gross margin | 0.00% | 95.88% |
| Operating margin | 0.00% | -56.17% |
| Net margin | 0.00% | -153.28% |
Growth (annualized)
| Metric | ESLA | KPTI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.47% |
| Total return CAGR (5Y) | -46.34% | -62.18% |
Frequently asked
- How have ESLA and KPTI total returns compared?
- Over the past 5 years, ESLA delivered -46.34% and KPTI delivered -62.18% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.